Healthcare [ 5/13 ] | Biotechnology [ 44/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 20, 24 | -2.08 Decreased by -47.52% | -1.17 Decreased by -77.78% |
| Nov 6, 23 | -1.32 Decreased by -23.36% | -1.2 Decreased by -10% |
| Aug 7, 23 | -1.54 Decreased by -45.28% | -1.22 Decreased by -26.23% |
| May 8, 23 | -0.26 Increased by +74.76% | -1.04 Increased by +75% |
| Feb 27, 23 | -1.41 Decreased by -56.67% | -1.14 Decreased by -23.68% |
| Nov 7, 22 | -1.07 Decreased by -15.05% | -1.08 Increased by +0.93% |
| Aug 9, 22 | -1.06 Decreased by -23.26% | -1.21 Increased by +12.4% |
| May 2, 22 | -1.03 Decreased by -32.05% | -1 Decreased by -3% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 57.79 M Increased by +243.08% | -62.2 M Decreased by -31.68% | Decreased by -107.62% Increased by +61.62% |
| Jun 30, 23 | 46.7 M Increased by +429.49% | -67.17 M Decreased by -56.81% | Decreased by -143.83% Increased by +70.39% |
| Mar 31, 23 | 94.58 M Increased by +N/A% | -11.22 M Increased by +72.62% | Decreased by -11.86% Decreased by N/A% |
| Dec 31, 22 | 24.37 M Increased by +N/A% | -66.76 M Decreased by -96.5% | Decreased by -273.94% Decreased by N/A% |
| Sep 30, 22 | 16.85 M Increased by +N/A% | -47.23 M Decreased by -35.41% | Decreased by -280.39% Decreased by N/A% |
| Jun 30, 22 | 8.82 M Increased by +N/A% | -42.84 M Decreased by -32.68% | Decreased by -485.68% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -40.98 M Decreased by -40.04% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -33.98 M Decreased by -16.5% | Decreased by N/A% Decreased by N/A% |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.